Skip to main content

Entera Bio Ltd

For the period ended Dec 31, 2023. Filed Mar 8, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 8, 2024

ENTX$3.25+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 16. Form 10-K Summary

Not applicable.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 8, 2024ENTERA BIO LTD.
By:/s/ Miranda Toledano
Miranda Toledano
Chief Executive Officer and Director

KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Miranda Toledano and Dana Yaacov-Garbelli, or any of them, each acting alone, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstituting, for such person and in his name, place and stead, in any and all capacities, to sign this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

NameTitleDate
/s/ Miranda ToledanoChief Executive Officer and DirectorMarch 8, 2024
Miranda Toledano(Principal Executive Officer)
/s/ Dana Yaacov-GarbeliChief Financial OfficerMarch 8, 2024
Dana Yaacov-Garbeli(Principal Financial and Accounting Officer)
/s/ Gerald LiebermanDirectorMarch 8, 2024
Gerald Lieberman
/s/ Roger J. GarceauDirectorMarch 8, 2024
Roger J. Garceau
/s/ Ron MayronDirectorMarch 8, 2024
Ron Mayron
/s/ Yonatan MalcaDirectorMarch 8, 2024
Yonatan Malca
/s/ Sean EllisDirectorMarch 8, 2024
Sean Ellis
/s/ Gerald M. OstrovDirectorMarch 8, 2024
Gerald M. Ostrov
/s/ Haya TaitelDirectorMarch 8, 2024
Haya Taitel
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.